Gene polymorphism at serotonin 5-HT1A receptors: Moving toward personalized medicine for psychosis and mood deficits?

Schizophrenia Research: Recent Advances

Volumn , Issue , 2012, Pages 337-358

  Newman Tancredi, Adrian ^a   Albert, Paul R ^b  

^a NeuroAct Communication   (France)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877980829     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (130)

1. Newman-Tancredi A, Kleven MS: Comparative pharmacology of antipsychotics possessing combined dopamine D(2) and serotonin 5-HT (1A) receptor properties. Psychopharmacology (2011)).
2. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27, 1159-72 (2003).
3. Kapur S, Mamo D: Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27, 1081-90 (2003).
4. Meltzer HY, Horiguchi M, Massey BW: The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) (2011).
5. Meltzer HY, Sumiyoshi T: Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 195, 98-102 (2008).
6. Newman-Tancredi A: The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 11, 802-12 (2010).
7. Prinssen EP, Colpaert FC, Koek W: 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453, 217-21 (2002).
8. Wadenberg ML, Ahlenius S: Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm Gen Sect 83, 43-53 (1991).
9. Auclair AL, Kleven MS, Barret-Grevoz C, et al.: Differences among conventional, atypical and novel putative D2/5-HT1A antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. Behav Brain Res 203, 288-95 (2009).
10. Yoshida K, Sugita T, Higuchi H, Hishikawa Y: Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry 13, 421-2 (1998).
11. Goff DC, Midha KK, Brotman AW, et al.: An open trial of buspirone added to neuroleptics in schizophrenic patients. Journal of clinical psychopharmacology 11, 193-7 (1991).
12. Sumiyoshi T, Matsui M, Nohara S, et al.: Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. The American journal of psychiatry 158, 1722-5 (2001).
13. Bardin L, Kleven MS, Barret-Grevoz C, Depoortere R, Newman-Tancredi A: Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 31, 1869-79 (2006).
14. Millan MJ: Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 295, 853-61 (2000).
15. Green AR: Neuropharmacology of 5-hydroxytryptamine. Br J Pharmacol 147 Suppl 1, S145-52 (2006).
16. Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F: The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29, 252-65 (2004).
17. Ichikawa J, Ishii H, Bonaccorso S, et al.: 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76, 1521-31 (2001).
18. Assie MB, Ravailhe V, Faucillon V, Newman-Tancredi A: Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315, 265-72 (2005).
19. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ: Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 93, 1251-62 (1999).
20. Bortolozzi A, Masana M, Diaz-Mataix L, et al.: Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors. Int J Neuropsychopharmacol, 1-16 (2010).
21. Sumiyoshi T, Bubenikova-Valesova V, Horacek J, Bert B: Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Advances in therapy 25, 1037-56 (2008).
22. Sumiyoshi T, Matsui M, Yamashita I, et al.: The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biological psychiatry 49, 861-8 (2001).
23. Meltzer HY, Sumiyoshi T: Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behavioural brain research 195, 98-102 (2008).
24. McCreary AC, Jones CA: Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism. Curr Pharm Des 16, 516-21 (2010).
25. Newman-Tancredi A, Chaput C, Verriele L, Millan MJ: Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology 35, 119-21 (1996).
26. Bartoszyk GD, Roos C, Ziegler H: 5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacology 35, 1645-6 (1996).
27. Bengtsson HJ, Kullberg A, Millan MJ, Hjorth S: The role of 5-HT1A autoreceptors and alpha1-adrenoceptors in the modulation of 5-HT release--III. Clozapine and the novel putative antipsychotic S 16924. Neuropharmacology 37, 349-56 (1998).
28. Rollema H, Lu Y, Schmidt AW, Zorn SH: Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. European journal of pharmacology 338, R3-5 (1997).
29. Millan MJ, Schreiber R, Dekeyne A, et al.: S 16924 ((R)-2-[1-[2-(2, 3-dihydro-benzo[ 1, 4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286, 1356-73 (1998).
30. Albert PR, Francois BL: Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy. Frontiers in neuroscience 4, 35 (2010).
31. Albert PR, Le Francois B, Millar AM: Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness. Mol Brain 4, 21 (2011).
32. Le Francois B, Czesak M, Steubl D, Albert PR: Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 55, 977-85 (2008).
33. Wu S, Comings DE: A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatric genetics 9, 105-6 (1999).
34. Lemonde S, Turecki G, Bakish D, et al.: Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23, 8788-99 (2003).
35. Lemonde S, Turecki G, Bakish D, et al.: Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. The Journal of neuroscience: the official journal of the Society for Neuroscience 23, 878-899 (2003).
36. Czesak M, Lemonde S, Peterson EA, Rogaeva A, Albert PR: Cell-specific repressor or enhancer activities of Deaf-1 at a serotonin 1A receptor gene polymorphism. J Neurosci 26, 1864-71 (2006).
37. Jacobsen KX, Vanderluit JL, Slack RS, Albert PR: HES1 regulates 5-HT1A receptor gene transcription at a functional polymorphism: essential role in developmental expression. Mol Cell Neurosci 38, 349-58 (2008).
38. Szewczyk B, Albert PR, Burns AM, et al.: Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. Int JNeuropsychopharmacol 12, 155-68 (2009).
39. Parsey RV, Oquendo MA, Ogden RT, et al.: Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 59, 106-13 (2006).
40. Sullivan GM, Ogden RT, Oquendo MA, et al.: Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol Psychiatry 66, 223-30 (2009).
41. Parsey RV, Ogden RT, Miller JM, et al.: Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biological psychiatry 68, 170-8 (2010).
42. David SP, Murthy NV, Rabiner EA, et al.: A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci 25, 2586-90 (2005).
43. Iyo AH, Kieran N, Chandran A, et al.: Differential regulation of the serotonin 1 A transcriptional modulators five prime repressor element under dual repression-1 and nuclear-deformed epidermal autoregulatory factor by chronic stress. Neuroscience 163, 1119-27 (2009).
44. Kieran N, Ou XM, Iyo AH: Chronic social defeat downregulates the 5-HT1A receptor but not Freud-1 or NUDR in the rat prefrontal cortex. Neuroscience letters 469, 380-4 (2010).
45. Ou XM, Storring JM, Kushwaha N, Albert PR: Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene. J Biol Chem 276, 14299-307 (2001).
46. Wissink S, Meijer O, Pearce D, van Der Burg B, van Der Saag PT: Regulation of the rat serotonin-1A receptor gene by corticosteroids. The Journal of biological chemistry 275, 1321-6 (2000).
47. Kageyama R, Ohtsuka T, Hatakeyama J, Ohsawa R: Roles of bHLH genes in neural stem cell differentiation. Exp Cell Res 306, 343-8 (2005).
48. Deng DR, Djalali S, Holtje M, et al.: Embryonic and postnatal development of the serotonergic raphe system and its target regions in 5-HT1A receptor deletion or overexpressing mouse mutants. Neuroscience 147, 388-402 (2007).
49. Rumajogee P, Verge D, Hanoun N, et al.: Adaption of the serotoninergic neuronal phenotype in the absence of 5-HT autoreceptors or the 5-HT transporter: involvement of BDNF and cAMP. Eur J Neurosci 19, 937-44 (2004).
50. Kushwaha N, Albert PR: Coupling of 5-HT1A autoreceptors to inhibition of mitogen-activated protein kinase activation via G beta gamma subunit signaling. Eur J Neurosci 21, 721-32 (2005).
51. Goswami DB, May WL, Stockmeier CA, Austin MC: Transcriptional expression of serotonergic regulators in laser-captured microdissected dorsal raphe neurons of subjects with major depressive disorder: sex-specific differences. Journal of neurochemistry 112, 397-409 (2010).
52. Pilot-Storck F, Chopin E, Rual JF, et al.: Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor. Mol Cell Proteomics 9, 1578-93 (2010).
53. Carlson PJ, Bain E, Tinsley R, et al.: Serotonin-1A receptor binding in bipolar depression before and after mood stabilizer treatment. Bipolar Disorders 9 (Suppl 1), 26-27 (2007).
54. Le Francois B, Czesak M, Millar AM, et al. Altered transcriptional regulation of 5-HT1A receptors by Deaf-1 in vivo: increase in autoreceptor levels and decrease in 5-HT levels. in The neurobiology of depression: revisiting the serotonin hypothesis., Vol. 33 (eds. Descarries L, Albert PR & Benkelfat C) 22 (Groupe de recherche sur le systéme nerveux central, Montréal, Québec, 2011).
55. Richardson-Jones JW, Craige CP, Guiard BP, et al.: 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 65, 40-52 (2010).
56. Richardson-Jones JW, Craige CP, Nguyen TH, et al.: Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. The Journal of neuroscience: the official journal of the Society for Neuroscience 31, 6008-18 (2011).
57. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR: Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 7, 501-6 (2004).
58. Savitz J, Lucki I, Drevets WC: 5-HT(1A) receptor function in major depressive disorder. ProgNeurobiol 88, 17-31 (2009).
59. Albert PR, Francois BL: Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy. Front Neurosci 4, 35 (2010).
60. Kishi T, Tsunoka T, Ikeda M, et al.: Serotonin 1A receptor gene and major depressive disorder: an association study and meta-analysis. J Hum Genet 54, 629-33 (2009).
61. Noro M, Antonijevic I, Forray C, et al.: 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. International clinical psychopharmacology 25, 228-31 (2010).
62. Chipman P, Jorm AF, Tan XY, Easteal S: No association between the serotonin-1A receptor gene single nucleotide polymorphism rs6295C/G and symptoms of anxiety or depression, and no interaction between the polymorphism and environmental stressors of childhood anxiety or recent stressful life events on anxiety or depression. Psychiatric genetics 20, 8-13 (2010).
63. Illi A, Setala-Soikkeli E, Viikki M, et al.: 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 20, 1125-8 (2009).
64. Kim HS, Sherman DK, Taylor SE, et al.: Culture, serotonin receptor polymorphism and locus of attention. Soc Cogn Affect Neurosci 5, 212-8 (2010).
65. Lenze EJ, Shardell M, Ferrell RE, et al.: Association of serotonin-1A and 2A receptor promoter polymorphisms with depressive symptoms and functional recovery in elderly persons after hip fracture. J Affect Disord 111, 61-6 (2008).
66. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR: Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. The international journal of neuropsychopharmacology /official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 7, 501-6 (2004).
67. Molina E, Cervilla J, Rivera M, et al.: Polymorphic variation at the serotonin 1-A receptor gene is associated with comorbid depression and generalized anxiety. Psychiatric genetics (2011).
68. Rothe C, Gutknecht L, Freitag C, et al.: Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. Int J Neuropsychopharmacol 7, 189-92 (2004).
69. Choi WS, Lee BH, Yang JC, Kim YK: Association Study between 5-HT1A Receptor Gene C(-1019)G Polymorphism and Panic Disorder in a Korean Population. Psychiatry Investig 7, 141-6 (2010).
70. Dhingra V, Magnay JL, O'Brien PM, et al.: Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstet Gynecol 110, 788-92 (2007).
71. Shim SH, Hwangbo Y, Kwon YJ, et al.: A case-control association study of serotonin 1A receptor gene and tryptophan hydroxylase 2 gene in attention deficit hyperactivity disorder. Progress in neuro-psychopharmacology & biological psychiatry 34, 974-9 (2010).
72. Zetzsche T, Preuss UW, Bondy B, et al.: 5-HT1A receptor gene C-1019 G polymorphism and amygdala volume in borderline personality disorder. Genes Brain Behav 7, 306-13 (2008).
73. Ni X, Chan D, Chan K, McMain S, Kennedy JL: Serotonin genes and gene-gene interactions in borderline personality disorder in a matched case-control study. Progress in neuro-psychopharmacology & biological psychiatry 33, 128-33 (2009).
74. Lothe A, Boni C, Costes N, et al.: Association between triallelic polymorphism of the serotonin transporter and [18F]MPPF binding potential at 5-HT1A receptors in healthy subjects. Neuroimage 47, 482-92 (2009).
75. Karg K, Burmeister M, Shedden K, Sen S: The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Archives of general psychiatry 68, 444-54 (2011).
76. Borg J, Henningsson S, Saijo T, et al.: Serotonin transporter genotype is associated with cognitive performance but not regional 5-HT1A receptor binding in humans. Int J Neuropsychopharmacol 12, 783-92 (2009).
77. Anguelova M, Benkelfat C, Turecki G: A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Molecular psychiatry 8, 646-53 (2003).
78. David SP, Murthy NV, Rabiner EA, et al.: A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. The Journal of neuroscience: the official journal of the Society for Neuroscience 25, 2586-90 (2005).
79. Kraus MR, Al-Taie O, Schafer A, et al.: Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 132, 1279-86 (2007).
80. Serretti A, Artioli P, Lorenzi C, et al.: The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 7, 453-60 (2004).
81. Zhang K, Xu Q, Xu Y, et al.: The combined effects of the 5-HTTLPR and 5-HTR1A genes modulates the relationship between negative life events and major depressive disorder in a Chinese population. Journal of affective disorders 114, 224-31 (2009).
82. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L: Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. Journal of psychopharmacology 19, 166-72 (2005).
83. Domschke K, Braun M, Ohrmann P, et al.: Association of the functional-1019C/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 9, 349-55 (2006).
84. Dannlowski U, Ohrmann P, Bauer J, et al.: Serotonergic genes modulate amygdala activity in major depression. Genes, brain, and behavior 6, 672-6 (2007).
85. Anttila S, Huuhka K, Huuhka M, et al.: Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. Journal of neural transmission 114, 1065-8 (2007).
86. Mossner R, Schuhmacher A, Kuhn KU, et al.: Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 19, 91-4 (2009).
87. Schmitz A, Kirsch P, Reuter M, et al.: The 5-HT1A C(-1019)G polymorphism, personality and electrodermal reactivity in a reward/punishment paradigm. Int J Neuropsychopharmacol 12, 383-92 (2009).
88. Videtic A, Zupanc T, Pregelj P, et al.: Suicide, stress and serotonin receptor 1A promoter polymorphism-1019C>G in Slovenian suicide victims. European archives of psychiatry and clinical neuroscience 259, 234-8 (2009).
89. Zanardi R, Magri L, Rossini D, et al.: Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 17, 651-7 (2007).
90. Lee YS, Choi SW, Han DH, Kim DJ, Joe KH: Clinical manifestation of alcohol withdrawal symptoms related to genetic polymorphisms of two serotonin receptors and serotonin transporter. Eur Addict Res 15, 39-46 (2009).
91. Parsey RV, Olvet DM, Oquendo MA, et al.: Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 31, 1745-9 (2006).
92. Beste C, Heil M, Domschke K, Konrad C: The relevance of the functional 5-HT1A receptor polymorphism for attention and working memory processes during mental rotation of characters. Neuropsychologia 48, 1248-54 (2010).
93. Huang YY, Battistuzzi C, Oquendo MA, et al.: Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol 7, 441-51 (2004).
94. Kishi T, Okochi T, Tsunoka T, et al.: Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis. Psychiatry research 185, 20-6 (2011).
95. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L: Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 163, 1826-9 (2006).
96. Wang L, Fang C, Zhang A, et al.: The--1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. JPsychopharmacol 22, 904-9 (2008).
97. Sumiyoshi T, Tsunoda M, Higuchi Y, et al.: Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia. Adv Ther 27, 307-13 (2010).
98. Thomas P: Psychosocial and economic issues related to physical health in psychiatric illness. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 18 Suppl 2, S115-20 (2008).
99. Patel A, Everitt B, Knapp M, et al.: Schizophrenia patients with cognitive deficits: factors associated with costs. Schizophrenia bulletin 32, 776-85 (2006).
100. Nagai T, Murai R, Matsui K, et al.: Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202, 315-28 (2009).
101. Bruins Slot LA, Kleven MS, Newman-Tancredi A: Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49, 996-1006 (2005).
102. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F: In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 191, 745-58 (2007).
103. Stahl SM, Sommer B, Allers KA: Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder. J Sex Med (2010).
104. Newman-Tancredi A, Heusler P, Martel JC, et al.: Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. Int J Neuropsychopharmacol 11, 293-307 (2008).
105. Newman-Tancredi A: Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders. Neuropsychiatry 1, 149-164 (2011).
106. Llado-Pelfort L, Assie MB, Newman-Tancredi A, Artigas F, Celada P: Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors. Br J Pharmacol 160, 1929-40 (2010).
107. Assie MB, Bardin L, Auclair AL, et al.: F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. Int J Neuropsychopharmacol 13, 1285-98 (2010).
108. Depoortere R, Auclair AL, Bardin L, et al.: F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur Neuropsychopharmacol 20, 641-54 (2010).
109. Newman-Tancredi A, Martel JC, Assie MB, et al.: Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol 156, 338-53 (2009).
110. McIlwain ME, Harrison J, Wheeler AJ, Russell BR: Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatric disease and treatment 7, 135-49 (2011).
111. Villafuerte SM, Vallabhaneni K, Sliwerska E, et al.: SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 19, 281-91 (2009).
112. Wu Y, Xu Y, Sun Y, et al.: Association between the serotonin 1A receptor C(-1019)G polymorphism and major depressive disorder in the northern Han ethnic group in China. Chin Med J (Engl) 121, 874-6 (2008).
113. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ: Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 16, 498-503 (2006).
114. Parsey RV, Olvet DM, Oquendo MA, et al.: Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 31, 1745-9 (2006).
115. Hong CJ, Chen TJ, Yu YW, Tsai SJ: Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 6, 27-33 (2006).
116. Lin E, Chen PS, Chang HH, et al.: Interaction of serotonin-related genes affects shortterm antidepressant response in major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry 33, 1167-72 (2009).
117. Bosia M, Anselmetti S, Bechi M, et al.: Effect of 5-HT1A-receptor functional polymorphism on Theory of Mind performances in schizophrenia. Psychiatry research (2010).
118. Kishi T, Tsunoka T, Ikeda M, et al.: Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology 58, 452-6 (2010).
119. Benedetti F, Radaelli D, Poletti S, et al.: Association of the C(-1019)G 5-HT1A promoter polymorphism with exposure to stressors preceding hospitalization for bipolar depression. Journal of affective disorders (2011).
120. Blaya C, Salum GA, Moorjani P, et al.: Panic disorder and serotonergic genes (SLC6A4, HTR1A and HTR2A): Association and interaction with childhood trauma and parenting. Neuroscience letters 485, 11-5 (2010).
121. Yevtushenko OO, Oros MM, Reynolds GP: Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord 123, 308-11 (2010).
122. Sawiniec J, Borkowski K, Ginalska G, Lewandowska-Stanek H: Association between 5-hydroxytryptamine 1A receptor gene polymorphism and suicidal behavior. Przegl Lek 64, 208-11 (2007).
123. Zupanc T, Pregelj P, Tomori M, Komel R, Paska AV: No association between polymorphisms in four serotonin receptor genes, serotonin transporter gene and alcohol-related suicide. Psychiatria Danubina 22, 522-7 (2010).
124. Serretti A, Calati R, Giegling I, et al.: Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. J Psychiatr Res 43, 519-25 (2009).
125. Serretti A, Mandelli L, Giegling I, et al.: HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. American journal of medical genetics. Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 144B, 291-9 (2007).
126. Yoon HK, Kim YK: TPH2-703G/T SNP may have important effect on susceptibility to suicidal behavior in major depression. Progress in neuro-psychopharmacology & biological psychiatry 33, 403-9 (2009).
127. Benko A, Lazary J, Molnar E, et al.: Significant association between the C(-1019)G functional polymorphism of the HTR1A gene and impulsivity. American journal of medical genetics. Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 153B, 592-9 (2010).
128. Beste C, Domschke K, Kolev V, et al.: Functional 5-HT1a receptor polymorphism selectively modulates error-specific subprocesses of performance monitoring. Hum Brain Mapp 31, 621-30 (2010).
129. Koller G, Bondy B, Preuss UW, Zill P, Soyka M: The C(-1019)G 5-HT1A promoter polymorphism and personality traits: no evidence for significant association in alcoholic patients. Behav Brain Funct 2, 7 (2006).
130. Lim SW, Ha J, Shin DW, Woo HY, Kim KH: Associations between the serotonin-1A receptor C(-1019)G polymorphism and disordered eating symptoms in female adolescents. J Neural Transm 117, 773-9 (2010).